Kiora Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Equity Incentive Plan (Tables)

Equity Incentive Plan (Tables)

6 Months Ended

Jun. 30, 2016

Share Based Compensation Option And Incentive Plan [Abstract]

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

The following is a summary of stock option activity for the six months ended June 30, 2016 and 2015:

	Number of Options		Weighted-Average Exercise Price		Weighted-Average Contractual Life (In Years)
Six Months Ended June 30, 2015
Outstanding at Beginning of Year		752,372	$	0.91		4.55
Granted		435,393		5.80		9.63
Exercised		(23,075)	$	0.65
Expired		(8,600)	$	0.65
Outstanding at End of Period		1,156,090	$	2.69		4.84

Exercisable at End of Period		841,031	$	2.70		4.75

Vested and Expected to Vest at End of Period		841,031	$	2.70		4.75

	Number of Options		Weighted-Average Exercise Price		Weighted-Average Contractual Life (In Years)
Six Months Ended June 30, 2016
Outstanding at Beginning of Year		1,277,367	$	2.75		4.94
Granted		252,256		2.96		9.70
Exercised		(86,765)	$	0.65
Forfeited		(12,362)	$	3.93
Outstanding at End of Period		1,430,496	$	2.95		5.23

Exercisable at End of Period		909,868	$	2.84		4.38

Vested and Expected to Vest at End of Period		909,868	$	2.84		4.38

Employee and Non Employee Service Share Based Compensation Allocation off Recognized Period Costs [Table Text Block]

The total stock-based compensation expense for employees and non-employees is included in the accompanying condensed consolidated statements of operations and as follows:

	Six Months Ended June 30,
	2016		2015
Research and Development	$	18,600	$	202,191
General and Administrative		218,804		573,104
	$	237,404	$	775,295